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Estimating the magnitude of cancer overdiagnosis in 
Australia
Paul P Glasziou1 , Mark A Jones1, Thanya Pathirana2, Alexandra L Barratt3, Katy JL Bell3
The burden of cancer is increasing rapidly,
1 including in 
Australia,2 partly because of ageing populations, reduced 
competing mortality from cardiovascular disease, and 
changes in exposure to risk factors for cancer. A further con-
tributor is overdiagnosis, or the diagnosis of cancer in people 
who would never have experienced symptoms or harm had the 
cancer remained undetected and untreated.3,4 Overdiagnosis of 
certain screen- detected cancers is common,5 including 20–50% 
of prostate cancer6 and 11–19% of breast cancer diagnoses.7
Cancer can also be overdiagnosed outside screening pro-
grams. Overdiagnosis of thyroid cancer8 is attributable to 
incidental detection during investigations of unrelated prob-
lems;9 overdiagnosis of renal cancer and melanoma is less well 
investigated.10
Overdiagnosis is important because of the associated iatrogenic 
harms and costs.3,11 Harms include the psychosocial impact of 
unnecessary cancer diagnoses, such as the increased suicide risk 
for men after being diagnosed with prostate cancer.12,13 Cancer 
treatments such as surgery, radiotherapy, endocrine therapy, 
and chemotherapy can cause physical harm, but the risks are 
considered acceptable if diagnosis is appropriate. When some-
one is unnecessarily diagnosed with cancer, however, they can 
only be harmed by treatment, not helped.4
Concerns about the overdiagnosis and overtreatment of cancer 
have led to calls to investigate the problem.5,14 To facilitate the 
evaluation of interventions for reducing overdiagnosis, we esti-
mated overdiagnosis levels in Australia for five of the seven can-
cers for which overdiagnosis has been documented:4 melanoma, 
and breast, prostate, thyroid and renal cancers. Neuroblastoma 
was not included because neuroblastoma screening is not un-
dertaken in Australia, and lung cancer was excluded because de-
clines in smoking rates and the unquantified uptake of screening 
complicate the assessment of overdiagnosis.
Methods
We aimed to estimate the proportion of cancer diagnoses in 
Australia that might reasonably be attributed to overdiagnosis 
by calculating and comparing current and past lifetime risks 
of cancer, a method we developed for assessing prostate cancer 
overdiagnosis.15
Excess lifetime risk for five cancers with recognised 
overdiagnosis potential
We analysed data routinely collected by the Australian 
Institute of Health and Welfare.16 We extracted data on cancer- 
specific diagnoses, cancer- specific deaths, all deaths, and pop-
ulation numbers to calculate, separately for women and men, 
differences in the lifetime risks of being diagnosed with spe-
cific cancers during in 1982 and in 2012. The comparator year 
(1982) was the first for which publicly available national data 
were available; further, there was no breast cancer screening 
program in 1982, little informal screening for prostate can-
cer or melanoma, and ultrasound and computed tomography 
(CT) screening that could detect incidental thyroid and renal 
cancers was infrequent. The index year (2012) was the most 
recent year for which data on the included cancers (invasive 
and in situ) were available. We assumed that by 2012 older 
people were exposed to early detection (screening or inciden-
tal detection on imaging) when younger, so that any effects of 
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Abstract
Objectives: To estimate the proportion of cancer diagnoses in 
Australia that might reasonably be attributed to overdiagnosis by 
comparing current and past lifetime risks of cancer.
Design, setting, and participants: Routinely collected Australian 
Institute of Health and Welfare national data were analysed to 
estimate recent (2012) and historical (1982) lifetime risks (adjusted 
for competing risk of death and changes in risk factors) of 
diagnoses with five cancers: prostate, breast, renal, thyroid cancers, 
and melanoma.
Main outcome measure: Difference in lifetime risks of cancer 
diagnosis between 1982 and 2012, interpreted as probable 
overdiagnosis.
Results: For women, absolute lifetime risk increased by 3.4 
percentage points for breast cancer (invasive cancers, 1.7 
percentage points), 0.6 percentage point for renal cancer, 1.0 
percentage point for thyroid cancer, and 5.1 percentage points 
for melanoma (invasive melanoma, 0.7 percentage point). An 
estimated 22% of breast cancers (invasive cancers, 13%), 58% 
of renal cancers, 73% of thyroid cancers, and 54% of melanomas 
(invasive melanoma, 15%) were overdiagnosed, or 18% of all cancer 
diagnoses (8% of invasive cancer diagnoses). For men, absolute 
lifetime risk increased by 8.2 percentage points for prostate cancer, 
0.8 percentage point for renal cancer, 0.4 percentage point for 
thyroid cancer, and 8.0 percentage points for melanoma (invasive 
melanoma, 1.5 percentage points). An estimated 42% of prostate 
cancers, 42% of renal cancers, 73% of thyroid cancers, and 58% 
of melanomas (invasive melanomas, 22%) were overdiagnosed, or 
24% of all cancer diagnoses (16% of invasive cancer diagnoses). 
Alternative assumptions slightly modified the estimates for 
overdiagnosis of breast cancer and melanoma.
Conclusions: About 11 000 cancers in women and 18 000 in men 
may be overdiagnosed each year. Rates of overdiagnosis need to 
be reduced and health services should monitor emerging areas of 
overdiagnosis.
The known: Overdiagnosis of some common cancers is a problem 
in developed countries, including Australia.
The new: After analysing changes in absolute lifetime risks for 
prostate, breast, renal, thyroid cancers and melanoma between 
1982 and 2012, we estimated that 18% of all cancers diagnosed in 
women (ie, 11 000 diagnoses each year), and 24% of those in men 
(18 000 each year) are overdiagnosed cancers.
The implications: Cancer overdiagnosis is a substantial problem 
that urgently requires changes in public health policy.
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early detection in preventing clinical presentation at an older 
age would be apparent. The AIHW data we analysed included 
only diagnoses of primary cancer, and only the first such di-
agnosis for a cancer type in an individual, consistent with in-
ternational practice.
We estimated lifetime risks using the Devcan 6.7.6 software of the 
United States National Cancer Institute (https ://surve illance. 
cancer.gov/devcan). Devcan applies the statistical methods 
described by Fay and colleagues,17 estimating lifetime risk by 
summing the estimated probabilities of new cancer- specific 
diagnoses for each age group, adjusted for the competing 
risk of dying from other causes. We analysed data by 5- year 
age group (0–85 years, and 85 years or more). To account for 
changes in mortality between 1982 and 2012, we applied the 
2012 mortality distribution (cancer- specific and all- cause mor-
tality data) to the 1982 cancer incidence data, increasing the es-
timated lifetime risk of a cancer diagnosis in 1982 to reflect the 
general increase in longevity between 1982 and 2012. The pro-
portion (percentage) of cancers deemed to have been overdiag-
nosed was estimated as:
where PY = lifetime probability of cancer diagnosis in year Y.
To estimate 95% confidence intervals (CIs) for our estimates of 
numbers overdiagnosed, we assumed Poisson distributions for 
the population estimates of cancers in 2012 and 1982. For exam-
ple: for prostate cancer, as the number of cancers in 2012 was 
20  759 and the estimated number in 1982 was 12  123, the es-
timated number of overdiagnoses was 8636 and the standard 
error 
√
(20 759 + 12 123), or 181.3; the 95% CI was consequently 
8636 ± 1.96 × 181.3 (or 8281–8991).
Adjusting for in situ cancers and changed prevalence of risk 
factors
For breast cancer, we adjusted the 1982 lifetime risk for 
changes in the prevalence of risk factors (primarily changes 
in reproductive factors) between 1982 and 2012. An adjustment 
factor was calculated from changes in the probability of di-
agnosis in women under 45 years of age, assuming that any 
changes in this age group would not be substantially affected 
by screening:
where P< 45, Y = probability of breast cancer diagnosis in women 
under 45 in year Y. We applied this adjustment factor to the life-
time probability of a breast cancer diagnosis (including in situ 
cancers) in 1982 to estimate the lifetime probability of breast 
cancer diagnosis in 1982, assuming 2012 risk factor levels. To ac-
count for in situ cancers likely to have been diagnosed but not 
recorded in registries in 1982 we multiplied the adjusted 1982 
estimate by 1.02.18,19
For melanoma, we multiplied the 1982 lifetime risk by 1.126 for 
women and by 1.101 for men to account for in situ cancers likely to 
have been diagnosed but not recorded in registries.20 We then mul-
tiplied these estimates by an adjustment factor for changes in cu-
mulative sun exposure between 1982 and 2012, using two methods:
• adjusted according to published annual proportional 
changes in age-standardised rates of thick melanomas 
(thickness greater than 1 mm), reported as yearly increases 
of 2.7% for women and 4.3% for men for the 12 years 
1982–9420 and 0.7% for women and 1.1% for men for the 17 
years 1995–2012;21 and
• as a sensitivity analysis, adjusted according to changes in 
mortality from 1975–79 to 1985–89.22
The final adjustment factors for our primary method (thick mel-
anomas) were:
We applied these adjustment factors to the lifetime probability 
of a melanoma diagnosis (including in situ cancers) in 1982 to 
estimate the lifetime probability of melanoma diagnosis in 1982, 
assuming 2012 risk factor levels.
Total excess lifetime risk of cancer (overdiagnosis)
To estimate the proportion of all cancer diagnoses in 2012 that 
might reasonably be deemed overdiagnosis, we first estimated 
the numbers of overdiagnosed breast, prostate, renal, thyroid 
cancers and melanoma (total number of specific cancer diagno-
ses multiplied by estimated overdiagnosis proportion for each 
cancer) and divided the sum of these estimates by the total num-
ber of cancer diagnoses of any type. We assumed that other can-
cer types were not overdiagnosed.
Other invasive cancers
In a further analysis, we estimated the change in risk of other 
invasive cancers (ie, invasive cancers other than prostate, 
breast, renal, thyroid cancers and melanoma) between 1982 
and 2012 by subtracting the combined lifetime probability 
of the five specific invasive cancers from the overall lifetime 
probability of any invasive cancer, then applying the formula 
for deriving the proportion of cancers deemed to have been 
overdiagnosed.
Sensitivity analyses
For breast cancer, we repeated our calculations with different 
age criteria (< 40 years, < 50 years). For melanoma, we applied an 
alternative adjustment for changes in the incidence of risk factors 
(eg, ultraviolet radiation exposure), based on changes in mela-
noma mortality between 1975–79 and 1985–89, during which pe-
riod a beneficial effect of informal screening was unlikely.
Potential effects of changes in body mass index
For breast,23 prostate,24 renal,25 and thyroid cancers,26 we esti-
mated the expected impact of obesity by including estimates of 
changes in relative risk with increasing body mass index (BMI), 
based on Australian mean BMI data.27
Ethics approval
In this negligible risk research study, we analysed publicly avail-
able datasets of non- identifiable aggregated data, and our inves-
tigation was therefore exempt from formal ethics review.
Results
Cancer diagnoses in women
The absolute lifetime risk of diagnosis increased between 1982 
and 2012 by 3.4 percentage points for breast cancer (invasive 
100∗(P2012−P1982)∕P2012
(P
<45, 2012−P<45, 1982)∕P<45, 1982
Women: P1982×1.126×1.027
12×1.00717 =P1982×1.748
Men: P1982×1.101×1.043
12×1.01117 =P1982×2.198
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breast cancer, 1.7 percentage points), 0.6 percentage point for 
renal cancer, 1.0 percentage point for thyroid cancer, and 5.1 per-
centage points for melanoma (invasive melanoma, 0.7 percent-
age point). We estimated that 22% of breast cancers (invasive 
breast cancer, 13%), 58% of renal cancers, 73% of thyroid cancers, 
and 54% of melanomas (invasive melanoma, 15%) were overdi-
agnosed, or 18% of all cancer diagnoses in women in 2012 (8% of 
all invasive cancer diagnoses) (Box 1).
The lifetime absolute risk of any invasive cancer for women in-
creased by 8.6 percentage points (Box 2). Overdiagnosis of invasive 
breast, renal, thyroid cancer and melanoma explained 47% of this 
increase. The remaining 53% was explained by increases in other 
invasive cancers (most notably, the 3.8 percentage point increase in 
lifetime risk of lung cancer; Supporting Information, table 1).
Cancer diagnoses in men
The absolute lifetime risks of being diagnosed with cancer in-
creased by 8.2 percentage points for prostate cancer, 0.8 per-
centage point for renal cancer, 0.4 percentage point for thyroid 
cancer, and 8.0 percentage points for melanoma (invasive mela-
noma, 1.5 percentage points). We estimated that 42% of prostate 
cancers, 42% of renal cancers, 73% of thyroid cancers, and 58% of 
melanomas (22% of invasive melanomas) were overdiagnosed, 
or 24% of all cancer diagnoses in men in 2012 (16% of all invasive 
cancer diagnoses) (Box 3).
The absolute lifetime risk of any invasive cancer increased by 
10.9 percentage points (Box 2). Overdiagnosis of invasive pros-
tate, renal, and thyroid cancers and of melanoma explained 97% 
of this increase.
Sensitivity analyses
Estimates of breast cancer overdiagnosis after adjusting for in-
creased breast cancer incidence in women under 40, 45, or 50 years 
of age ranged between 16% and 28% when including ductal car-
cinomas in situ, and between 6% and 19% for invasive cancers 
(Supporting Information, table 2). Estimates for invasive melanoma 
overdiagnosis adjusted for earlier trends in mortality (instead of 
concurrent trends in thick lesions) were 5 percentage points higher 
for both men and women (Supporting Information, table 3).
Potential effects of changes in body- mass index
The risk of post- menopausal breast cancer has been reported to 
increase by 12% per 5 kg/m2 rise in BMI;23 from 1989 to 2012, 
the mean BMI for Australian women increased by 1.8 kg/m2.27 
Consequently, the expected increase in postmenopausal breast 
cancers would be 1.12 × 1.8/5 or 1.04, a 4% relative increase; and 
the overdiagnosis rate would be smaller: about 19% (100 × [0.153 
– 0.119 × 1.04]/0.153) rather than 22%.
For prostate cancer, the UK Biobank study24 found that relative 
risk for prostate cancer declined by 10% per 5  kg/m2 rise in 
BMI, although it noted that the finding might be explained by 
prostate- specific antigen being assessed less frequently in obese 
men. Were this estimate used for the expected change in lifetime 
probability, overdiagnosis would be greater than the 42% we 
report.
For renal cancer, the relative risk has been reported to increase 
by 56% per standard deviation rise in BMI, but this finding 
may have been influenced by investigation rates.25 Based on 
changes in mean BMI in Australia from 1989 to 2012,27 this 
yields relative risks of 1.56  ×  1.8/7.5 or 1.13 for women and 
1.56 × 1.8/5.2 or 1.19 for men. Were these estimates used for the 
expected increase in lifetime probability, overdiagnosis rates 
would be modestly smaller than the 58% (women) and 42% 
(men) we report.
For thyroid cancer, six of nine studies26 found that thyroid can-
cer prevalence rose with increasing BMI, but the magnitude of 
the increase was generally less than that we calculated for renal 
cancer, so that the impact on estimated overdiagnosis rates 
would be negligible.
Discussion
We estimated that overdiagnosis accounted for about 18% of 
cancer diagnoses in women in Australia during 2012, and about 
1 Estimated number of cancer overdiagnoses in women, Australia, 2012
Cancer
Lifetime probability of 
diagnosis Change in 
probability, 
1982–2012
Overdiagnosis 
proportion†
Cancer  
diagnoses, 2012
Estimated  
overdiagnoses, 
2012 (95% CI)1982* 2012
Breast
Including ductal carcinomas in situ 0.119 0.153 0.034 22% 17 825 3957 (3601–4313)
Invasive only 0.117 0.134 0.017 13% 15 348 1949 (1610–2288)
Melanoma
Including in situ carcinomas 0.044 0.095 0.051 54% 10 492 5634 (5386–5882)
Invasive only 0.039 0.046 0.007 15% 5088 774 (580–968)
Thyroid 0.0038 0.0140 0.0102 73% 1168 851 (774–928)
Renal 0.0046 0.0110 0.0064 58% 1143 665 (584–746)
Other invasive cancers 0.290 0.335 0.045 — 32 401 —
All cancers
Including in situ carcinomas (breast 
cancer, melanoma)‡
63 029 11 107 (18%)
Invasive only 55 148 4239 (8%)
CI = confidence interval. * After applying 2012 mortality age distribution and adjustment for changes in risk factor levels for breast cancer and melanoma. † Change in probability (1982–2012)/
probability (2012). ‡ Assuming no overdiagnosis for other cancers. ◆
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24% of diagnoses in men. That is, about 11 000 cancers in women 
and 18 000 in men may be overdiagnosed each year. Although 
proportional rates of overdiagnosis were highest for renal and 
thyroid cancers and for melanoma, absolute numbers of overdi-
agnosis were greatest for breast cancer and prostate cancer be-
cause of their higher baseline prevalence.
Studies in other countries have found similar rates of overdiag-
nosis of specific cancer types.10 However, ours is the first study to 
estimate overall cancer overdiagnosis on a national level. A recent 
British analysis did not estimate an overall figure, but found that 
the “incidence of 10 of the 20 most common cancers in the UK has 
increased by more than 50% in both sexes since the 1980s.”28 These 
cancers included breast, kidney, prostate, thyroid cancers and mel-
anoma, but also non- Hodgkin lymphoma, oral, cervical, liver, and 
uterine cancers. In Australia, the incidence of cervical and oral can-
cers has declined, while the incidence and mortality of liver cancer 
have increased,29 suggesting these cancers are not overdiagnosed. 
Although the incidence of non- Hodgkin lymphoma and uterine 
cancer has each increased (and mortality has declined),29 this may 
be explained by factors other than overdiagnosis. We therefore es-
timated overdiagnosis only for cancers with the typical epidemi-
ologic signature of overdiagnosis: breast, prostate, kidney, thyroid 
cancers and melanoma (for which lifetime mortality has changed 
little in absolute terms; Supporting Information, table 4).30 UK 
cancer statistics released in January 2019 show very high survival 
rates for people with early stage cancers of these types, providing 
further evidence of probable overdiagnosis: 5- year survival of 99% 
for stage 1 breast cancer, 100% for stage 1 prostate cancer, 100% 
for stage 1 melanoma, 89% for stage 1 kidney cancer, and 88% for 
thyroid cancer of any stage.31
The reason for overdiagnosis differs by cancer type. 
Overdiagnosis of breast cancers is largely attributable to 
the national screening program, that of prostate cancers 
and melanoma to opportunistic but extensive screening 
in Australia. Renal cancer overdiagnosis appears to be 
largely linked with cancers detected as incidental find-
ings during abdominal imaging for an unrelated rea-
son (incidentalomas). Overdiagnosis of thyroid cancer 
is related to both incidentalomas and to excessive inves-
tigation of thyroid function test abnormalities. Different 
approaches to reducing rates of overdiagnosis are there-
fore required for different cancer types.
We recognise that eliminating overdiagnosis alto-
gether is unlikely, but reduction is feasible. For exam-
ple, the number of thyroid cancer diagnoses in South 
Korea was reduced by one- third by discouraging ul-
trasound screening;32 several countries have reduced 
prostate cancer incidence and overdiagnosis with 
more targeted and less frequent prostate screening.33 
However, the potential benefits of changes to early 
detection practices for breast and prostate cancer, for 
example, need to be balanced against harms, and clin-
ical and community input should be encouraged. A 
complementary solution would be tests that identify 
only clinically important cancers, or at least correctly 
identify low risk cancers as being such.
Limitations
Despite the robustness of our data — mandatory, na-
tional registration of all cancers in Australia since 1982 
provided us with a nationally representative longitudi-
nal dataset — our analysis was subject to limitations. 
First, we assumed no overdiagnosis in 1982, a reason-
able assumption given the lower levels of screening. However, the 
incidence of prostate cancer increased slightly in New South Wales 
during 1972–1982 without a change in mortality,34 suggesting 
some overdiagnosis. Second, we assumed no overdiagnosis of can-
cers other than the five we specified. The lifetime probability for 
men of all other invasive cancers increased slightly, and declines 
for specific cancers (such as lung cancer) may have offset increases 
in others, some of which may be overdiagnosed. For women, there 
was a modest increase for other invasive cancers, largely explained 
by the increased diagnosis of lung cancer (unlikely to be overdi-
agnosis), but other cancers may have been overdiagnosed. To esti-
mate the total excess risk for all cancers we summed the risks for 
the individual and other cancers, and for people with more than 
one type of cancer each was counted separately.
We adjusted for some risk factor changes known to have in-
creased the risk of the included cancers during the period of our 
study, and we acknowledge the uncertainty inherent in this pro-
cess. Our adjusted estimate of breast cancer overdiagnosis (22%), 
however, is consistent with the findings of an independent panel 
assessment analysing data from randomised trials,7 and lies in 
the middle of the range of estimates provided by observational 
studies.10 Melanoma overdiagnosis has not been estimated in 
randomised trials or observational studies,35 but analysis of 
population data suggests it is probably substantial4,36 and that 
in situ melanomas account for most overdiagnosed melanomas, 
consistent with our findings.
Conclusion
Despite the uncertainties in our estimates, the estimated rates 
of cancer overdiagnosis have important implications for health 
2 Changes in lifetime risks of cancer, adjusted for changes in competing 
mortality
* For “Combined cancers”, the numbers for the individual cancers are summed; that is, people with more 
than one type of cancer are counted more than once. ◆
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policy. First, rates of avoidable overdiagnosis need to be reduced to 
the lowest level compatible with targeted screening and appropri-
ate investigation. We also need to examine strategies for reducing 
overtreatment of low risk prostate, breast and thyroid cancers. Our 
analysis provides a method for deriving baseline estimates of the 
total burden of cancer overdiagnosis in Australia against which the 
effectiveness of such interventions could be measured. A second, 
and perhaps more important implication is that health services 
need to be alert to new areas of overdiagnosis and to detect them 
early. This could be an important role for the Australian Institute 
of Health and Welfare and state cancer registries; increased test, 
incidence, or treatment rates, without corresponding rises in mor-
tality, could indicate emerging areas of overdiagnosis.37
Acknowledgements: We received funding from the Australian National Health 
and Medical Research Council (NHMRC Fellowship 1080042; Centres of Research 
Excellence grant 1104136 [Creating sustainable health care: ensuring new diagnostics 
avoid harms, improve outcomes and direct resources wisely], and Program 
grant 1113532 [Using healthcare wisely: reducing inappropriate use of tests and 
treatments]).
Competing interests: No relevant disclosures.
Received 15 April 2019, accepted 27 September 2019 ■
© 2019 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd 
on behalf of AMPCo Pty Ltd
3 Estimated number of cancer overdiagnoses in men, Australia, 2012
Cancer
Lifetime probability of 
diagnosis Change in 
probability, 
1982–2012
Overdiagnosis 
proportion†
Cancer diagnoses, 
2012
Estimated  
overdiagnoses,  
2012 (95% CI)1982* 2012
Prostate 0.115 0.197 0.082 42% 20 759 8636 (8281–8991)
Melanoma
Including in situ carcinomas 0.059 0.139 0.080 58% 14 436 8315 (8034–8596)
Invasive only 0.054 0.069 0.015 22% 7151 1552 (1331–1773)
Thyroid 0.0014 0.0052 0.0038 33% 661 483 (426–540)
Renal 0.011 0.019 0.008 42% 2045 861 (749–973)
Other invasive cancers 0.420 0.423 0.003 — 39 452 —
All cancers
Including in situ carcinomas 
(melanoma)‡
77 353 18 295 (24%)
Invasive only 70 068 11 531 (16%)
* After applying 2012 mortality age distribution and adjustment for changes in risk factor levels for melanoma. † Change in probability (1982–2012)/probability (2012). ‡ Assuming no 
 overdiagnosis for other cancers. ◆
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